Literature DB >> 34494178

Pre-exposure Prophylaxis Persistence Among Greek Sexual Minority Men: Results from PrEP for Greece (P4G) Study.

Mweya Waetjen1, Martha Papadopoulou2, Rey Flores3,4, Vana Sypsa5, Sotiris Roussos5, Sophocles Chanos1, Nikos Dedes6, Chuanhong Liao3, Dimitrios Paraskevis5, Angelos Hatzakis5, John Schneider7,8,9,10, Mina Psichogiou2.   

Abstract

Nearly half the new HIV infections in Greece occur in sexual minority men, yet pre-exposure prophylaxis is not currently supported in the national HIV program. We examined factors associated with PrEP persistence among Greek SMM in PrEP for Greece, the first PrEP study in Greece. Participants (n = 100) were recruited from 2016 to 2018 through respondent-driven sampling among SMM in Athens, receiving supplies for daily PrEP at interval visits over 12-months. PrEP persistence, operationalized as Total PrEP Time, was high, 74% of participants achieving perfect persistence. Higher alcohol risk scores (OR 1.27, 95% CI 1.08-1.49) and adherence to HIV testing guidelines (OR 1.23, 95% CI 1.00-1.51) were associated with persistence. Housing impermanence (OR 0.14, 95% CI 0.04-0.48) and serostatus disclosure concerns (OR 0.77, 95% CI 0.60-0.97) were associated with limited PrEP persistence. While PrEP persistence among Greek SMM is high, socioeconomic factors and societal attitudes may challenge prevention efforts.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Greece; HIV; MSM; Persistence; PrEP

Mesh:

Substances:

Year:  2021        PMID: 34494178     DOI: 10.1007/s10461-021-03459-7

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  1 in total

1.  A Network Approach to Determine Optimization of PrEP Uptake in Athens, Greece.

Authors:  Tom Fouché; Natascha Del Vecchio; Martha Papadopoulou; Vana Sypsa; Sotirios Roussos; Dimitrios Paraskevis; Sophocles Chanos; Nikos Dedes; Aditya Khanna; Anna Hotton; Angelos Hatzakis; Mina Psichogiou; John A Schneider
Journal:  AIDS Behav       Date:  2022-02-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.